Skip to content

Comparison of incidence of Nausea and Vomiting in Postoperative Abdominal surgery Patients Using IV PCA Fentanyl versus Morphine

Comparison of incidence of Nausea and Vomiting in Postoperative Abdominal surgery Patients Using IV PCA Fentanyl versus Morphine

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260219009
Enrollment
102
Registered
2026-02-19
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting(PONV) in patient undergoing laparoscopic abdominal surgery using intravenous patient-controlled analgesia (IV PCA) intravenous patient-controlled analgesia, Postoperative nausea and vomiting, laparoscopic abdominal surgery

Interventions

Morphine 1 mg/mL of IV PCA,Fentanyl 10 mcg/mL of IV PCA
Active Comparator Drug,Active Comparator Drug
Morphine,Fentanyl

Sponsors

Faculty of Medicine, Khon Kaen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients scheduled for elective laparoscopic abdominal surgery, including both intraperitoneal and retroperitoneal approaches, 2.Adult patients aged between 18 and 75 years, 3.American Society of Anesthesiologists (ASA) physical status I, II, or III, 4.Patients at high risk for postoperative nausea and vomiting (PONV), defined by an Apfel score of three or higher.

Exclusion criteria

Exclusion criteria: 1.Refusal to participate in the study, 2.Patients undergoing gynecological surgery, 3.Patients receiving combined regional anesthesia, such as central neuraxial blocks or peripheral nerve blocks, 4.History of drug allergy or contraindications to the medications used in this study, 5.Pregnant patients, 6.Chronic kidney disease stage three or higher, 7.Patients with liver failure. Body Mass Index (BMI) of thirty or higher, 8.Patients with obstructive sleep apnea (OSA), 9.Inability to understand or operate the intravenous patient-controlled analgesia (IV PCA) device, 10.Communication barriers, 11.impaired decision-making capacity, 12.Patients with chronic pain conditions

Design outcomes

Primary

MeasureTime frame
incidence of postoperative nausea at 12, 24, 48 hour postoperatively Incidence of postoperative nausea (Yes/No)

Secondary

MeasureTime frame
incidence of vomiting at 12, 24, 48 hour postoperatively Yes/No,Severity of nausea at 12, 24, 48 hour postoperatively visual analog scale,incidence of pruritus at 12, 24, 48 hour postoperatively Yes/No,incidence of respiratory distress at 12, 24, 48 hour postoperatively Yes/No,level of conscious at 12, 24, 48 hour postoperatively sedation score(0,1,2,3),Total opioid consumption at 12, 24, 48 hour postoperatively volume of drug(ml),Patient satisfaction at 48 hour postoperatively 0,1,2,3,4,5

Countries

Thailand

Contacts

Public ContactKanokwan Pholsan

Faculty of Medicine, Khon Kaen University

kanokwanph@kkumail.com0885612647

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026